| 3 min read
By combining human-derived data with AI-driven discovery, the partnership seeks to tackle Parkinson’s disease heterogeneity and improve target selection.
| 4 min read
Enzymes once viewed as rigid specialists are now being repurposed as modular tools, revealing latent chemical capabilities and enabling new approaches to molecule construction.
| 4 min read
Alzheimer’s diagnosis tests, AI-designed DNA circuits, bacterial insights, and more led the news this week. News
| 5 min read
While faster reviews could bring life-saving treatments to patients sooner, compressed timelines could also limit regulatory scrutiny and strain FDA resources.
| 4 min read
LYMPHIR delivers targeted therapy for a rare and incurable form of skin lymphoma while opening doors for broader immuno-oncology applications.
| 4 min read
Combining unified data architecture with standards-based hardware allows pharma companies to scale processes faster and more reliably.
| 4 min read
Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline.
| 2 min read
The approach pairs ultrasound-induced tumor cell death with real-time antigen capture to drive both local and systemic immune responses.
| 4 min read
A new drug may restore sexual function for men for months after just three days of dosing, offering hope for those who don’t respond to existing therapies.
| 4 min read
Novel Alzheimer’s screening tests, promising weight loss drug data, an AI model linking sleep to disease risk, and more led the news this week.
| 4 min read
By reengineering small-molecule chemistry for automation, Excelsior aims to remove a long-standing barrier to AI-driven drug discovery.
| 4 min read
The FDA’s National Priority Voucher program aims to cut standard review times from potentially years to months, raising questions about safety, access, and public health impact.
